News - Teva Pharmaceutical Industries, Markets & Marketing


Popular Filters

1 to 25 of 36 results

Teva launches first generic Lovaza in USA

Teva launches first generic Lovaza in USA


Israel-based Teva Pharmaceutical Industries says it has received US Food and Drug Administration approval…

Cardio-vascularGenericsGlaxoSmithKlineLovazaMarkets & MarketingRegulationTeva Pharmaceutical IndustriesUSA

Modest growth forecast for global migraine market to 2023

Modest growth forecast for global migraine market to 2023


The global migraine treatment market value is expected to undergo a modest increase over the coming years,…

CoLucid PharmaceuticalsGloballamiditanMarkets & MarketingMerck & CoMK-1602NeurologicalNuPathePharmaceuticalTeva Pharmaceutical IndustriesZecuity

Alexza’s partner Teva launches antipsychotic Adasuve in USA

Alexza’s partner Teva launches antipsychotic Adasuve in USA


US drug developer Alexza Pharmaceuticals says that its marketing partner, Israel-based generic drugs…

AdasuveAlexza PharmaceuticalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical IndustriesUSA

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs


The local subsidiary of Israeli generics giant Teva Pharmaceutical Industries has launched Lonquex (lipegfilgrastim)…

AmgenBiosimilarsGenericsLonquexMarkets & MarketingNorthern EuropeOncologyTeva Pharmaceutical IndustriesUK

Teva receives subpoenas over Copaxone and Azilect marketing

Teva receives subpoenas over Copaxone and Azilect marketing


The US Department of Justice is investigating Israel drugmaker Teva Pharmaceutical Industries’ marketing…

AzilectCopaxoneLegalMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Teva launches authorized generic of Detrol in USA

Teva launches authorized generic of Detrol in USA


Israel’s Teva Pharmaceutical Industries, the world’s largest generic drugmaker, says it has launched…

Detrol LAGenericsGenito-urinaryMarkets & MarketingNorth AmericaPfizerTeva Pharmaceutical IndustriesUSA

Prostate cancer market to almost double to $8 billion by 2019, says GBI


The prostate cancer treatment market is forecast to increase from $4.1 billion in 2012 to $8 billion…

Active BiotechAstellas PharmaJohnson & JohnsonMarkets & MarketingOncoGenexOncologyPharmaceuticalTeva Pharmaceutical IndustriesXofigoXtandiZytiga

Teva updates on Lonquex and Granix launches

Teva updates on Lonquex and Granix launches


Israel-based Teva Pharmaceutical Industries announced two significant additions to its global oncology…

balugrastimBiosimilarsEuropeGenericsLonquexMarkets & MarketingNorth AmericaOncologyRegulationTeva Pharmaceutical Industries

Teva's exclusive launch of generic Niaspan in the USA


Israel-based Teva Pharmaceutical Industries (NYSE: TEVA), the world biggest maker of generic drugs, on…

AbbVieCardio-vascularMarkets & MarketingNiaspanNorth AmericaTeva Pharmaceutical Industries

MS therapeutics market led by Copaxone


The multiple sclerosis (MS) therapeutics market has been forecast to increase at a compound annual growth…

CopaxoneMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Generic Temodar launches in USA


Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) and Perrigo (NYSE: PRGO;TASE) today…

GenericsMarkets & MarketingMerck & CoNorth AmericaOncologyPerrigoTemodarTeva Pharmaceutical Industries

Surge in drug approvals, R&D productivity and investor confidence to drive Pharma expansion through 2018, says Evaluate


According to the newly-released World Preview 2013 report from market intelligence firm Evaluate, the…

AbbVieBiotechnologyGilead SciencesGlobalHumiraMarkets & MarketingNovartisPfizerPharmaceuticalRegulationResearchsofosbuvirTeva Pharmaceutical Industries

Teva and Actavis debut generic Viagra in Europe


The patent on Viagra (sildenafil) expired last Friday (June 21) in the UK and some other European countries,…

ActavisEuropeGenericsMarkets & MarketingMen's HealthReproductivesildenafilTeva Pharmaceutical IndustriesViagra

Teva pays $40 million upfront to market Alexza's Adasuve in USA


The US subsidiary of Israeli generics giant Teva Pharmaceuticals Industries (NYSE: TEVA) has entered…

AdasuveAlexza PharmaceuticalLicensingMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical Industries

US FDA approves Lupin's generic version of Teva's Seasonique and Taro's Topicort


Indian drugmaker Lupin (BSE: 500257) saw its shares gain 2.3% to 659.65 rupees by close of trading on…

DayseeDermatologicalsGenericsLupinMarkets & MarketingNorth AmericaPharmaceuticalRegulationReproductiveSeasoniqueTaro PharmaceuticalsTeva Pharmaceutical IndustriesTopicort

Watson confirms Velcade patent challenge; Mylan debuts generic Nordette


US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) on Friday confirmed that its subsidiary Actavis…

ActavisGenericsMarkets & MarketingMillennium PharmaceuticalsMylan LaboratoriesNordette 28North AmericaOncologyPatentsReproductiveTeva Pharmaceutical IndustriesVelcadeWatson Pharmaceuticals

Teva launches generic Aprovel in UK


The UK subsidiary of Israel's Teva Pharmaceutical Industries (NYSE: TEVA), the world's largest generic…

AprovelBristol-Myers SquibbCardio-vascularEuropeGenericsMarkets & MarketingSanofiTeva Pharmaceutical Industries

Ranbaxy debuts authorized Actos generic in USA, followed by Teva and Mylan


The US subsidiary of Ranbaxy Laboratories (AB: BO), India's largest drugmaker, has launched authorized…

ActoplusMetActosDiabetesGenericsMarkets & MarketingMylan LaboratoriesNorth AmericaRanbaxy LaboratoriesRegulationTakeda PharmaceuticalsTeva Pharmaceutical Industries

Johnson & Johnson close to settling over Risperdal marketing; SEC probes Teva


US health care giant Johnson & Johnson (NYSE: JNJ) has reached "an agreement in principle'' with the…

FinancialGenericsInvegaJanssenJohnson & JohnsonLegalMarkets & MarketingNatrecorNorth AmericaPharmaceuticalRisperdalTeva Pharmaceutical Industries

Patient share of Teva/Lundbeck's Azilect for Parkinson's continues to grow


Through examination of US patient-level claims data, that patient share of Azilect (rasagiline) - from…

AzilectLundbeckMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical Industries

EU Commission focus now on Servier and others re-perindopril antitrust issues


The European Commission has informed French independent pharmaceutical company Servier and several of…

Cardio-vascularEuropeGenericsLegalMarkets & MarketingMylan LaboratoriesPatentsperindoprilPharmaceuticalServierTeva Pharmaceutical Industries

Novartis and Teva announce expansion plans in Russia


Swiss drug major Novartis (NOVN: VX) has signed an agreement with RT-Biotechprom, one of Russia's largest…

EuropeFinancialGenericsMarkets & MarketingNovartisPharmaceuticalRT-BiotechpromTeva Pharmaceutical Industries

Teva launches copy version of Difflam in the UK


The UK subsidiary of Israeli generics giant Teva Pharmaceutical Industries (Nadaq: TEVA) has announced…

DifflamEuropeGenericsMarkets & MarketingMeda PharmaceuticalsNeurologicalOroezeTeva Pharmaceutical Industries

FDA delays once-a-day Prezista approval; finds counterfeit of Teva's Adderall


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Therapeutics division has received a complete…

AdderallAnti-viralsGenericsJanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPrezistaRegulationTeva Pharmaceutical Industries

1 to 25 of 36 results

Back to top